Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Leadership Launches

Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Companies Clinical Trials

EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody

If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.

Europe Approvals

Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped

The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.

Companies Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register